Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19

被引：35
|
作者：
Giovannoni, Gavin [1 ]
机构：
[1] Barts & London Queen Marys Sch Med & Dent, Blizard Inst, 4 Newark St, London E1 2AT, England
来源：
MULTIPLE SCLEROSIS AND RELATED DISORDERS | 2020年 / 41卷
关键词：
OCRELIZUMAB;
D O I：
10.1016/j.msard.2020.102135
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Longitudinal COVID-19 immune trajectories in patients with neurological autoimmunity on anti-CD20 therapy
    Bazzi, Sam A.
    Maguire, Cole
    Holay, Nisha
    Geltman, Janelle
    Hurley, Kerin
    DiPasquale, Chris
    Abigania, Melissa
    Olson, Eric
    Ehrlich, Lauren I. R.
    Triplett, Todd A.
    Melamed, Esther
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 68
  • [42] Does dosing frequency of anti-CD20 therapies blunt vaccine responses and increase COVID-19 susceptibility in patients with multiple sclerosis?
    Avasarala, Jagannadha
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 90 (12) : 3094 - 3096
  • [43] Association Between Anti-CD20 Therapies and COVID-19 Severity Among Patients With Relapsing-Remitting and Progressive Multiple Sclerosis
    Januel, Edouard
    Hajage, David
    Labauge, Pierre
    Maillart, Elisabeth
    De Seze, Jerome
    Zephir, Helene
    Pelletier, Jean
    Guilloton, Laurent
    Bensa, Caroline
    Heinzlef, Olivier
    Casez, Olivier
    Biotti, Damien
    Bourre, Bertrand
    Vukusic, Sandra
    Maurousset, Aude
    Berger, Eric
    Laplaud, David
    Lebrun-Frenay, Christine
    Dubessy, Anne-Laure
    Branger, Pierre
    Thouvenot, Eric
    Clavelou, Pierre
    Sellal, Francois
    Manchon, Eric
    Moreau, Thibault
    Papeix, Caroline
    Tubach, Florence
    Louapre, Celine
    JAMA NETWORK OPEN, 2023, 6 (06) : E2319766
  • [44] Effectiveness of anti-CD20 therapies after natalizumab
    Cunha, Carolina
    Matos, Sara
    Carvalho, Ines V.
    Cardoso, Joao
    Campelo, Isabel
    Feio, Jose
    Batista, Sonia
    Nunes, Carla
    Macario, Maria do Carmo
    Sousa, Livia Maria
    Correia, Ines
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 623 - 623
  • [45] Dental Adverse Effects of Anti-CD20 Therapies
    Bartak, Helene
    Fareh, Tasnim
    Ben Othman, Nouha
    Viard, Delphine
    Cohen, Mikael
    Rocher, Fanny
    Ewig, Elliot
    Drici, Milou-Daniel
    Lebrun-Frenay, Christine
    NEUROLOGY AND THERAPY, 2024, 13 (03) : 917 - 930
  • [46] Risk of COVID-19 infection in patients with rheumatic disease taking disease-modifying anti-rheumatic drugs
    Behnaz Yousefghahari
    Sanaz Navari
    Mahmoud Sadeghi
    Shima Soleimaniamiri
    Mohammadjafar Soleimaniamiri
    Behzad Heidari
    Mansour Babaei
    Kian Ghodrati
    Ardeshir Guran
    Hemmat Gholinia
    Clinical Rheumatology, 2021, 40 : 4309 - 4315
  • [47] Risk of COVID-19 infection in patients with rheumatic disease taking disease-modifying anti-rheumatic drugs
    Yousefghahari, Behnaz
    Navari, Sanaz
    Sadeghi, Mahmoud
    Soleimaniamiri, Shima
    Soleimaniamiri, Mohammadjafar
    Heidari, Behzad
    Babaei, Mansour
    Ghodrati, Kian
    Guran, Ardeshir
    Gholinia, Hemmat
    CLINICAL RHEUMATOLOGY, 2021, 40 (10) : 4309 - 4315
  • [48] Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies
    Fioravante Capone
    Matteo Lucchini
    Elisabetta Ferraro
    Assunta Bianco
    Mariagrazia Rossi
    Alessandra Cicia
    Antonio Cortese
    Alessandro Cruciani
    Valeria De Arcangelis
    Laura De Giglio
    Francesco Motolese
    Biagio Sancetta
    Massimiliano Mirabella
    Vincenzo Di Lazzaro
    Neurotherapeutics, 2022, 19 : 325 - 333
  • [49] Association between disease-modifying therapies and adverse clinical outcomes in multiple sclerosis patients with COVID-19 infection
    Maghbooli, Z.
    Aghababaei, Y.
    Hosseinpour, H.
    Fatahi, M.
    Varzandi, T.
    Hamtaee, S.
    Mohammad-Nabi, S.
    Eskandarieh, S.
    Aghighi, M.
    Moghadasi, A. Naser
    Sahraian, M.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (1_SUPPL) : 76 - 77
  • [50] Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies
    Capone, Fioravante
    Lucchini, Matteo
    Ferraro, Elisabetta
    Bianco, Assunta
    Rossi, Mariagrazia
    Cicia, Alessandra
    Cortese, Antonio
    Cruciani, Alessandro
    De Arcangelis, Valeria
    De Giglio, Laura
    Motolese, Francesco
    Sancetta, Biagio
    Mirabella, Massimiliano
    Di Lazzaro, Vincenzo
    NEUROTHERAPEUTICS, 2022, 19 (01) : 325 - 333
12345